Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SLC6A6 | P31641 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | APP | P05067 | 1/20 | 0.32 |
| ▸ | ENPEP | Q07075 | 4/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.30 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.30 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL766602 | 1.00 | PTGS1 (0.35) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL752524 | 0.83 | PTGS1 (0.36) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL28137092 | 0.78 | PTGS1 (0.36) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL28980311 | 0.78 | PTGS1 (0.36) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL14599499 | 0.77 | TP53 (0.36) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL16445311 | 0.76 | PTGS1 (0.31) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL2990953 | 0.75 | — | — | |
| SCHEMBL1919360 | 0.74 | LMNA (0.39) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL11489923 | 0.74 | PTGS1 (0.33) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL6043669 | 0.74 | TP53 (0.33) | TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10385337-B2 | Oligonucleotide end caps | ALNYLAM PHARMACEUTICALS, INC. (US) | 2019-08-20 | — | — | US | disclosed |
| EP-3424939-A1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | Alnylam Pharmaceuticals Inc. (US) | 2019-01-09 | — | — | EP | disclosed |
| US-20170107511-A1 | OLIGONUCLEOTIDE END CAPS | BANK OF AMERICA, N.A. | 2017-04-20 | — | — | US | disclosed |
| US-9512164-B2 | Oligonucleotide end caps | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-20160348110-A1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | ALNYLAM PHARMACEUTICALS INC (US) | 2016-12-01 | — | — | US | disclosed |
| US-9453043-B2 | Nucleic acid chemical modifications | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-20150210733-A1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | BANK OF AMERICA, N.A. | 2015-07-30 | — | — | US | disclosed |
| US-8975389-B2 | Nucleic acid chemical modifications | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-03-10 | — | — | US | disclosed |
| EP-2669290-A1 | Nucleic Acid Chemical Modifications | Alnylam Pharmaceuticals Inc. (US) | 2013-12-04 | — | — | EP | disclosed |
| EP-2403863-B1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | ALNYLAM PHARMACEUTICALS INC (US) | 2013-08-28 | — | — | EP | disclosed |
| US-20120142101-A1 | OLIGONUCLEOTIDE END CAPS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| US-20120071641-A1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| EP-2403863-A1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | Alnylam Pharmaceuticals Inc. (US) | 2012-01-11 | — | — | EP | disclosed |
| WO-2011005861-A9 | OLIGONUCLEOTIDE END CAPS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-08-11 | — | — | WO | disclosed |
| WO-2011005861-A1 | OLIGONUCLEOTIDE END CAPS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | WO | disclosed |
| WO-2010101951-A1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210733-A1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | NSUN2, RNMT, NSUN3 | PTGS1 2766/4885PDE4A 2126/4885LMNA 839/4885 |
| US-10385337-B2 | Oligonucleotide end caps | RNGTT, POLRMT, POLM | PTGS1 3702/4885PDE4A 623/4885LMNA 333/4885 |
| US-20120071641-A1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | NSUN2, RNMT, NSUN3 | PTGS1 2771/4885PDE4A 2160/4885LMNA 851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.